Advances in the treatment of transthyretin cardiac amyloidosis: Current and emerging therapies
- 20 October 2021
- journal article
- review article
- Published by Wiley in Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy
- Vol. 41 (12) , 1081-1091
Abstract
Transthyretin cardiac amyloidosis (ATTR‐CA) has been recognized as an underdiagnosed and undertreated cause of heart failure with often unrecognized multiorgan involvement. Guideline development and the establishment of nonbiopsy criteria for diagnosis of ATTR‐CA have led to an increased rate of diagnosis and hence patients referred for therapies. ATTR is a protein misfolding disorder where the TTR tetramer disassociates into monomers which form insoluble amyloid depositions in organs, including the heart. ATTR‐CA can be due to autosomal dominant transmitted gene mutation or due to misfolding of wild‐type TTR. Prior to 2019, there were no FDA‐approved pharmacological treatments for ATTR‐CA. Understanding of ATTR‐CA pathogenesis has enabled development of targeted strategies with novel disease‐modifying therapies. Current and emerging therapies for ATTR‐CA include (1) TTR gene silencing (siRNA, ASO, CRISPR/Cas9), (2) TTR tetramer stabilization, and (3) TTR amyloid fibril degradation. This review focuses on the pathophysiology of ATTR‐CA, diagnostic criteria, and addresses current and emerging treatments for this diverse disorder.Keywords
This publication has 49 references indexed in Scilit:
- Cooperative Stabilization of Transthyretin by Clusterin and DiflunisalBiochemistry, 2014
- Genetic Stabilization of Transthyretin, Cerebrovascular Disease, and Life ExpectancyArteriosclerosis, Thrombosis, and Vascular Biology, 2013
- Natural polyphenols inhibit different steps of the process of transthyretin (TTR) amyloid fibril formationFEBS Letters, 2011
- Synergy of combined Doxycycline/TUDCA treatment in lowering Transthyretin deposition and associated biomarkers: studies in FAP mouse modelsJournal of Translational Medicine, 2010
- Senile systemic amyloidosis affects 25% of the very aged and associates with genetic variation inalpha2‐macroglobulinandtau: A population‐based autopsy studyAnnals of Medicine, 2008
- Noninvasive Etiologic Diagnosis of Cardiac Amyloidosis Using 99m Tc-3,3-Diphosphono-1,2-Propanodicarboxylic Acid ScintigraphyJACC, 2005
- Prevention of Transthyretin Amyloid Disease by Changing Protein Misfolding EnergeticsScience, 2003
- Tabulation of human transthyretin (TTR) variants, 2003Amyloid, 2003
- Compound heterozygotes of transthyretin Met30 and transthyretin Met119 are protected from the devastating effects of familial amyloid polyneuropathyNeuromuscular Disorders, 1996
- Digoxin sensitivity in amyloid cardiomyopathy.Circulation, 1981